



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ATTY.'S DOCKET: CHAIN8A

In re Application of:) Art Unit:
)
 Benjamin CHAIN) Examiner:
)
 Appln. No.: NOT YET ASSIGNED) Washington, D.C.
)
 Filed: ON EVEN DATE HEREWITH) December 8, 2000
)
 For: CHIMERIC PEPTIDES AS)
 IMMUNOGENS, ANTIBODIES)
 THERETO, AND METHODS FOR...)

INFORMATION DISCLOSURE STATEMENT [IDS]

Honorable Commissioner of Patents and Trademarks
Washington, D.C. 20231

Sir :

This Information Disclosure Statement is submitted in accordance with 37 CFR §§1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

[X] 1. This IDS should be considered, in accordance with 37 CFR §1.97, as it is filed:

(Check one of the boxes A-D)

[X] A. within three months of the filing date of the above-identified national application or within three months of the entry into the national stage of the above-identified international application.

B. before the mailing date of a first office action on the merits.

C. after (A) and (B) above, but before final rejection or allowance, and Applicants have made the necessary certification (box "i" below) or paid the necessary fee (box "ii" below).

(Check one of the boxes "i" and "ii" below:)

i. Counsel certifies that, upon information and belief, each item of information listed herein was either

(a) first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS; or

(b) not cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of undersigned after making reasonable inquiry, was not known to any individual designated in §1.56(c) more than three months prior to the filing of this IDS.

(use one and delete other of following)

ii. A check (check no. _____) for the fee set forth in §1.17(p), presently believed to be \$240, is enclosed.

ii. Credit Card Payment Form, PTO-2038, is attached authorizing payment of the fee set forth in §1.17(p), presently believed to be \$240.

D. after (A), (B) and (C) above, but before payment of the issue fee: Applicant(s) petitions under 37 CFR §1.97(d) for consideration of this IDS.

Credit Card Payment Form, PTO-2038, is attached authorizing payment of the fee set forth in §1.17(i), presently believed to be \$130 is enclosed. Counsel certifies that, upon information and belief, each item of information listed herein was either

(Check one of the boxes "a" and "b" below)

[] (a) first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS; or

[] (b) was not cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned after making reasonable inquiry, was not known to any individual designated in §1.56(c) more than three months prior to the filing of this IDS.

[X] 2. In accordance with 37 CFR §1.98, this IDS includes a list (e.g., form PTO-1449) of all patents, publications, or other information submitted for consideration by the office, either incorporated into this IDS or as an attachment hereto. A copy of each document listed is attached, except as explained below.

(check boxes A and/or B and fill in blanks, if appropriate)

[] A. Document(s) _____ is (are) deemed substantially cumulative to document(s) _____, and, in accordance with §1.98(c), only a copy of each of the latter documents is enclosed.

[] B. Certain documents were previously cited by or submitted to the Office in the following prior application(s), which are relied upon under 35 U.S.C. 120:

(insert serial numbers and filing dates of prior applications)

Applicant(s) identifies these documents by attaching hereto copies of the forms PTO-892 and PTO-1449 from the files of the prior application(s) or a fresh PTO-1449 listing these documents, and request that they be considered and made of record in accordance with §1.98(d). Per 37 CFR §1.98(d), copies of these documents need not be filed in this application.

[] 3. Document(s) _____ is (are) not in the English language. In accordance with §1.98(c), Applicant(s) states:

[] An English translation of each document _____ (or of the pertinent portions thereof), or a copy of each corresponding English-language patent or application, or English-language abstract (or claim) is enclosed.

[] A concise explanation of the relevance of document(s) _____ is found in the attached _____ search report (see reply to Comment 68 in the preamble to the final rules; 1135 OG 13 at 20).

[] A concise explanation of the relevance of document(s) _____ is set forth as follows:

(insert concise explanation of relevance)

[] A concise explanation of the relevance of document(s) _____ can be found on page(s) _____ of the specification.

[] A concise explanation of document(s) _____ can be found on the attached sheet.

[X] 4. No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 and 68 in the preamble to the final rules; 1135 OG 13 at 20).


[] 5. Other information being provided for the examiner's consideration follows:

(insert other information)

6. In accordance with 37 CFR §§1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in §1.56 (b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant(s) reserves the right to prove that the date of publication is in fact different.

Respectfully submitted,

BROWDY AND NEIMARK
Attorneys for Applicant(s)

By: 

Allen C. Yun
Reg. No. 37,971

624 Ninth Street, N.W., Suite 300
Washington, D.C. 20001-5303
Telephone: (202) 628-5197
Facsimile: (202) 737-3528

FORM PTO-1449			U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO. CHAIN8A	SERIAL NO. Not Yet Assigned
LIST OF DOCUMENTS CITED BY APPLICANT (Use several sheets if necessary)			APPLICANT: Benjamin CHAIN		GROUP 12/08/00 675 USPTO 09/13/99
			FILING DATE: Even Date Herewith		
EXAMINER INITIALS	OTHER DOCUMENTS (include at least document number, publication date and country)				
AA	SCHENK et al., "Immunization with amyloid- β attenuates Alzheimer-disease-like pathology in the PDAPP mouse", Nature, 400:173-177 (July 1999)				
AB	Sharma et al., "Co-dominant and reciprocal T-helper cell activity of epitopic sequences and formation of junctional B-cell determinants in synthetic T:B chimeric immunogens", Vaccine, 11:1321-1326 (1993)				
AC	Ifversen et al., "Induction of primary antigen-specific immune responses in SCID-hu-PBL by coupled T-B epitopes", Immunology, 84:111-116 (1995)				
AD	O'Hern et al., "Colinear synthesis of an antigen-specific B-cell epitope with a 'promiscuous' tetanus toxin T-cell epitope: a synthetic peptide immunocontraceptive", Vaccine, 16:1761-1766 (1997)				
AE	Ho et al., "Identification of two promiscuous T cell epitopes from tetanus toxin", Eur. J. Immunol., 20:477-483 (1990)				
AF	Panina-Bordignon et al., "University immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells", Eur. J. Immunol., 19:2237-2242 (1989)				
AG	Valmori et al., "Use of human universally antigenic tetanus toxin T cell epitopes as carriers for human vaccination", The Journal of Immunology, 149:717-721 (July 15, 1992)				
AH	Valmori et al., "Functional analysis of two tetanus toxin universal T cell epitopes in their interaction with DR1101 and DR1104 alleles", Journal of Immunology, 2921-2929 (1994)				
AI	Schofield et al., "Sequences of the mouse F protein alleles and identification of a T cell epitope", Eur. J. Immunol., 21:1235-1240 (1991)				
AJ	Talwar et al., "The HSD-hCG vaccine prevents pregnancy in women: feasibility study of a reversible safe contraceptive vaccine", American Journal of Reproductive Immunology, 37:153-160 (1997)				
AK	Iwatsubo et al., "Short communication full-length amyloid- β (1-42(43)) and amino-terminally modified and truncated amyloid- β 42(43) deposit in diffuse plaques", American Journal of Pathology, 149:1823-1830 (December 1996)				
EXAMINER			DATE CONSIDERED		
EXAMINER: Initial if reference considered. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant.					